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Background
There is large body of evidence on the correlation
between chronic inflammatory diseases like rheumatoid
arthritis (RA) and increased risk of cardiovascular dis-
eases (CVD). Chronic inflammation is an independent
risk factor for the development of early atherosclerosis.
The possible role of anti TNF- a biologic drugs in redu-
cing this risk arouses great interest among the scientific
community. Many studies indicate the possibility that
anti-TNF-a agents may reduce CVD risk and mortality
in adult RA patients. There are only few data about the
pediatric population.
Aim
To determine the presence of early biomarkers of
endothelial dysfunction in juvenile idiopathic arthritis
(JIA) and to evaluate their improvement during anti
TNF-a treatment with etanercept.
Methods
We enrolled 30 children affected by JIA, all eligible for
anti-TNF-a treatment. All patients were examined at
baseline and after 6 months and 12 months of treatment
with etanercept. Disease activity score for each patient
was determined using JADAS (Juvenile Arthritis Disease
Activity Score). Laboratory parameters included acute
phase reactants (CRP and ESR), complete lipid profile,
pro-inflammatory cytokines (TNF-a,I L - 1 b, IL-6, IFN-g)
and biomarkers of oxidative stress and vascular inflam-
mation (8-iso-PGF2a, total nitric oxide, TXB2 and
PGE2).
Results
During the study all biomarkers of endothelial dysfunc-
tion progressively improved after 1 year of etanercept
treatment in JIA children. At t h es a m et i m ea l li n f l a m -
matory parameters and JADAS scores significantly
improved when compared to baseline. Pro-inflammatory
cytokines showed significant reduction both after 6 and
12 months of treatment; at 6 months a relative increase
in TNF-a and IL-6 was determined. Lipid profile, bio-
markers of endothelial activation (total nitric oxide,
PGE2,T X B 2)a n d8 - i s o - P G F 2a (a surrogate marker of
oxidized LDL) showed significant improvement during
treatment.
Conclusion
We demonstrated beneficial effect of 1-year etanercept
treatment on clinical disease activity, inflammatory
indexes and oxidative biomarkers in JIA children. The
role of inflammation on pre-atherosclerotic determi-
nants justify the need of precocious interventions in JIA,
in order to optimize the clinical outcome and to realize
primary prevention of cardiovascular events in
adulthood.
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